# FDA Advances Drug Transparency Rulemaking

The FDA’s fiscal 2027 transparency roadmap outlines anticipated rulemaking on disclosure of drug application status, a standardized patient medication guide, and prescription-drug advertising across modern media. The agency expects to propose a rule on complete response letters in October 2026. The signal identifies no contract award or solicitation; it also notes a separate FDA RFI on early-phase ibogaine trials.

- Pharmaceutical manufacturers, clinical-trial organizations, and regulatory and labeling service providers can assess how the anticipated proposals may affect disclosure controls, patient materials, and advertising practices; the roadmap describes planned rulemaking, not requirements already in effect.
- The complete-response-letter proposal is expected this month, October 2026. The signal provides no response deadline or procurement terms for the separate ibogaine-trial RFI.
- The developments may inform demand for regulatory, labeling, and clinical-trial support, but the roadmap itself does not establish a contract opportunity.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** October 06, 2026

### Government Entities
- Food and Drug Administration (FDA)

### Sources
- [FDA maps a 2027 transparency push - POLITICO](https://www.politico.com/newsletters/prescription-pulse/2026/10/06/fda-maps-a-2027-transparency-push-01107445) - Politico